Trump's Historic Cannabis Rescheduling: What Schedule III Actually Means for the Industry
The biggest federal cannabis policy shift in 55 years just happened. Here's what it means—and what it doesn't.
On December 18, 2025, President Donald Trump signed an executive order directing the Attorney General to complete the process of rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act.
"We have people begging for me to do this," Trump said during the Oval Office signing ceremony, surrounded by medical professionals. "Today I'm pleased to announce that I will be signing an executive order to reschedule marijuana from a Schedule I to a Schedule III controlled substance, with legitimate medical uses."
This is the most significant shift in federal cannabis policy since the Controlled Substances Act was enacted in 1970.
But what does it actually mean?
Let's cut through the hype and break down what this changes—and what it doesn't.
CannaSecure
What Just Happened: The Quick Version
For 55 years, cannabis has been classified as a Schedule I controlled substance—the same category as heroin, LSD, and ecstasy.
Schedule I substances are defined as having:
- High potential for abuse
- No currently accepted medical use
- Lack of accepted safety for use under medical supervision
Schedule III substances (like ketamine, Tylenol with codeine, and testosterone) are defined as having:
- Moderate-to-low potential for physical and psychological dependence
- Currently accepted medical use
- Lower abuse potential than Schedule I or II
Trump's executive order instructs Attorney General Pam Bondi to finalize the rescheduling process—moving cannabis out of Schedule I and into Schedule III.
The Road to Rescheduling: How We Got Here
This didn't start with Trump.
October 2022: President Biden directed HHS and the Attorney General to review how marijuana is scheduled under federal law.
August 2023: The U.S. Department of Health and Human Services (HHS) concluded a scientific review and recommended that cannabis be moved to Schedule III.
May 2024: The Department of Justice (DOJ) issued a proposed rule to reschedule marijuana.
August 2024: The DEA announced it would hold administrative hearings on the proposal, scheduled for January 21, 2025.
January 2025: The administrative hearing was postponed while an appeal was resolved.
December 18, 2025: Trump issued an executive order directing the Attorney General to "complete the rulemaking process related to rescheduling marijuana to Schedule III of the CSA in the most expeditious manner in accordance with Federal law."
The key difference: Biden initiated the process but didn't use executive authority to fast-track it. Trump is telling the DOJ to finalize it immediately—bypassing the stalled hearing process.
CannaSecure
What Schedule III DOES Change
1. Federal Recognition of Medical Use
This is the first time the federal government has openly recognized cannabis as having accepted medical use since the CSA was enacted in 1970.
That brings federal policy closer to reality:
- 38 states have medical cannabis programs
- 24 states have legalized adult-use cannabis
- Millions of patients use cannabis legally under state law
This shift reduces stigma and creates a foundation for future reform.
2. The End of 280E (The Cannabis Industry's Biggest Tax Burden)
This is the most immediate and impactful change for cannabis businesses.
What is 280E?
Section 280E of the Internal Revenue Code states:
"No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act)..."
Since cannabis has been Schedule I, state-licensed cannabis businesses cannot deduct normal business expenses like:
- Rent
- Payroll
- Marketing
- Utilities
- Insurance
- Professional services
They can only deduct Cost of Goods Sold (COGS)—direct costs of producing inventory.
The result: Effective tax rates of 70-80% for some cannabis operators.
When cannabis moves to Schedule III, 280E no longer applies.
Cannabis businesses will be able to deduct ordinary and necessary business expenses like any other business.
What this means:
- Immediate cash flow improvement
- Businesses can reinvest savings into growth, hiring, R&D
- Struggling operators get breathing room to survive
- Industry becomes financially viable
Estimated impact: Cannabis businesses could save 30-40% on federal taxes annually.
CannaSecure
3. Easier Research Access
As a Schedule I substance, cannabis research has been severely restricted:
- Researchers need DEA registration
- Limited legal supply (historically only from University of Mississippi)
- Burdensome approval processes
- Institutional reluctance (federal funding risk)
Schedule III opens doors:
- Lower regulatory barriers for research
- More institutions willing to study cannabis
- Potential for FDA-approved cannabis medications
- Better understanding of efficacy, dosing, safety
This matters for:
- Veterans with PTSD, chronic pain
- Cancer patients
- Epilepsy treatment (already approved: Epidiolex)
- Chronic pain management (opioid alternative research)
4. Reduced Stigma & Banking Improvements (Indirect)
Stigma: Federal recognition of medical use legitimizes cannabis in public discourse and policy.
Banking: While rescheduling doesn't solve the banking problem (cannabis businesses still can't access traditional banking without SAFE Banking Act passage), it signals federal acceptance that may make banks more comfortable.
Investment: Institutional investors and capital markets should take notice—federal policy is shifting.
What Schedule III DOES NOT Change
Be very clear: This is not legalization.
1. Cannabis Remains Federally Illegal for Recreational Use
Rescheduling does not legalize marijuana for adult recreational use.
Even as Schedule III:
- Simple possession remains a federal crime
- Interstate commerce remains illegal
- Federal employees still can't use cannabis
- Federal contractors still bound by drug-free workplace policies
- Immigration consequences still apply
State recreational programs still technically clash with federal law.
The federal government has opted not to crack down on state-licensed businesses—but that policy could change.
2. No Interstate Commerce
Cannabis businesses still cannot ship across state lines.
Each state's cannabis must be grown, processed, and sold within that state.
This means:
- No national cannabis brands (in the traditional sense)
- No economies of scale from centralized production
- Fragmented supply chains
- Higher costs for multi-state operators
CannaSecure
3. FDA Oversight (The New Challenge)
Here's where it gets complicated.
Schedule III substances are regulated medicines. That means:
- FDA approval required for cannabis to be prescribed as medicine
- Prescription required from licensed physicians
- Pharmaceutical standards for manufacturing, quality control, labeling
No FDA-approved cannabis products currently exist (except Epidiolex for epilepsy, which is CBD-only).
The industry concern:
State-licensed dispensaries sell cannabis without FDA approval and without prescriptions.
What happens when cannabis is a Schedule III controlled substance but there are no FDA-approved products?
Possible scenarios:
Scenario A (Optimistic): FDA creates a regulatory pathway for state-licensed cannabis similar to state pharmacy boards. State programs continue operating under a federal exemption framework.
Scenario B (Realistic): Dual system emerges:
- FDA-approved cannabis medications (prescriptions, pharmacies)
- State-licensed cannabis programs (continue as-is, federal tolerance)
Scenario C (Pessimistic): FDA/DEA begin enforcing pharmaceutical standards on state programs, requiring:
- GMP (Good Manufacturing Practice) facilities
- Clinical trials for product claims
- Prescription requirements
- Massive compliance costs
Industry leaders are concerned that without clarification, rescheduling could create MORE regulatory burden, not less.
4. No Criminal Justice Reform
Rescheduling does nothing for the tens of thousands of Americans incarcerated for cannabis offenses.
Federal cannabis convictions remain on the books.
State convictions remain (unless states offer expungement).
Advocates emphasize: Rescheduling is progress, but descheduling and expungement are still necessary for true justice.
5. No SAFE Banking Act Passage
Cannabis businesses still face banking challenges:
- Most banks won't serve cannabis clients (federal illegality risk)
- Cash-only operations create security risks
- Credit card processing limited
- Difficulty securing loans, lines of credit
SAFE Banking Act (separate legislation) is needed to fully solve banking issues.
Rescheduling may make banks more comfortable, but it doesn't eliminate the legal barriers.
Timeline: When Does This Actually Happen?
Trump's executive order says: "in the most expeditious manner in accordance with Federal law."
What that means:
The Attorney General (Pam Bondi) must:
- Resume the rescheduling rulemaking process (currently on hold)
- Issue a final rule (published in Federal Register)
- Allow time for the rule to take effect (typically 30-60 days after publication)
Realistic timeline:
- Best case: Q1 2026 (January-March)
- Likely case: Q2 2026 (April-June)
- Conservative case: Late 2026 (if appeals/delays occur)
For tax purposes:
If finalized in 2026, it's unlikely to be retroactive to prior years.
Cannabis businesses should prepare for:
- Potential effective date: January 1, 2026 (full year relief)
- Or mid-year effective date: Partial year relief
IRS guidance needed: How to handle transition year accounting, prior NOLs, etc.
What Cannabis Businesses Should Do Now
1. Prepare Your Accounting for 280E Relief
Action items:
- Review your chart of accounts
- Identify expenses currently non-deductible under 280E
- Prepare to reclassify COGS vs operating expenses
- Consult with cannabis-specialized CPA
Be ready for:
- Significantly lower tax bills (30-40% reduction)
- Improved cash flow
- Need to update financial projections
2. Don't Assume Retroactive Relief
Likely reality:
- Past taxes paid under 280E: Not refunded
- Unpaid past 280E taxes: Still owed
Recommendation: If you have unpaid 280E tax liabilities, work with IRS on installment agreements now.
3. Watch for FDA/DEA Guidance
The industry needs clarity on:
- How Schedule III affects state-licensed operations
- Whether FDA will create a cannabis regulatory pathway
- What compliance standards will be required
- How prescriptions (or lack thereof) will be handled
Stay plugged into:
- National Cannabis Industry Association (NCIA)
- U.S. Cannabis Roundtable (USCR)
- State cannabis associations
- Legal counsel specializing in cannabis law
4. Invest in Quality & Compliance Infrastructure
If cannabis moves toward pharmaceutical standards, businesses should:
- Implement GMP-compliant facilities
- Enhance quality control procedures
- Document everything (SOPs, batch records, testing)
- Consider ISO certifications
Larger operators may gain advantage if compliance costs rise.
5. Prepare for Increased Federal Scrutiny
Schedule III = Regulated medicine = DEA oversight
Expect:
- More rigorous inspections
- Enhanced record-keeping requirements
- Potential federal licensing/registration
- Enforcement of pharmaceutical standards
Industry Reactions: What Leaders Are Saying
Kyle Sherman (CEO, Flowhub):
"This is real progress. It removes an unfair tax burden. It reduces stigma. It opens the door to research, legitimacy, and long-term stability."
Vince C. Ning (Co-CEO, Nabis):
"Rescheduling will help accelerate research, reduce stigma, attract new investment, and ease some of the tax burdens that have held the industry back. The next transformation will happen when interstate commerce barriers between states are removed."
Paul Armentano (NORML Deputy Director):
"The Administration's order calling to remove the cannabis plant from its Schedule I classification validates the experiences of tens of millions of Americans... But while such a move potentially provides some benefits to patients, it still falls well short of the changes necessary to bring federal marijuana policy into the 21st century."
Jason Ortiz (Last Prisoner Project):
"Moving cannabis to a lower schedule does nothing for the tens of thousands of Americans still locked behind bars for actions that are now legal in most of the country."
The Bottom Line: Progress, Not Perfection
What rescheduling achieves:
✅ Federal recognition of medical use (finally)
✅ Elimination of 280E tax burden (huge financial relief)
✅ Easier research access (potential medical breakthroughs)
✅ Reduced stigma (cultural shift)
✅ Foundation for further reform
What rescheduling doesn't solve:
❌ Federal recreational legalization
❌ Interstate commerce
❌ Banking access (without SAFE Banking Act)
❌ Criminal justice (expungement, release)
❌ FDA regulatory pathway (still unclear)
❌ State program conflicts with federal law
Is this a win? Yes—the biggest federal cannabis policy shift in 55 years.
Is this enough? No—full descheduling, expungement, interstate commerce, and banking reform are still needed.
But it's real, measurable progress.
And for cannabis businesses struggling under 280E, it could be the difference between survival and closure.
What Happens Next?
Watch for:
- Final rule publication from DOJ/DEA (Q1-Q2 2026 likely)
- IRS guidance on transition accounting and 280E relief
- FDA announcement on cannabis regulatory pathway (or lack thereof)
- State regulatory responses (how states adapt to federal Schedule III)
- Congressional action (will this momentum lead to SAFE Banking, descheduling?)
This is not the end. It's the beginning of a new chapter.
For the first time in over 50 years, the federal government is acknowledging what millions of Americans already know: cannabis has legitimate medical value.
That recognition opens doors.
What happens next depends on how policymakers, regulators, businesses, and advocates push through those doors.
Stay Updated:
CannaSecure will continue monitoring federal rescheduling developments and provide updates as the process unfolds.
Subscribe for alerts when the final rule is published and IRS guidance is released.
